Skip to main navigation 2021 Press Releases Home / 2021 Press Releases Year 2021 NOV 15 PROTALIX BIOTHERAPEUTICS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES FINANCIAL AND BUSINESS UPDATE Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel , Nov. 15, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic PDF Version NOV 8 PROTALIX BIOTHERAPEUTICS TO RELEASE THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDE A FINANCIAL AND BUSINESS UPDATE ON NOVEMBER 15, 2021 Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel , Nov. 8, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins PDF Version OCT 15 PROTALIX BIOTHERAPEUTICS AND CHIESI GLOBAL RARE DISEASES ANNOUNCE FINAL DOSING OF LAST PATIENT IN PHASE III BALANCE CLINICAL TRIAL PRX-102 FOR THE TREATMENT OF FABRY DISEASE CARMIEL, Israel and BOSTON , Oct. 15, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant PDF Version OCT 11 PROTALIX BIOTHERAPEUTICS AND CHIESI GLOBAL RARE DISEASES PROVIDE REGULATORY UPDATE ON PRX-102 FOR THE TREATMENT OF FABRY DISEASE CARMIEL, Israel and BOSTON , Oct. 11, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant PDF Version AUG 26 PROTALIX BIOTHERAPEUTICS ANNOUNCES CLOSING OF PRIVATE NOTE EXCHANGE CARMIEL, Israel , Aug. 26, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based PDF Version AUG 16 PROTALIX BIOTHERAPEUTICS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND FINANCIAL AND BUSINESS UPDATE CARMIEL, Israel , Aug. 16, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based PDF Version AUG 13 PROTALIX BIOTHERAPEUTICS ANNOUNCES PRIVATE NOTE EXCHANGE CARMIEL, Israel , Aug. 13, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based PDF Version AUG 9 PROTALIX BIOTHERAPEUTICS TO RELEASE SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDE A FINANCIAL AND BUSINESS UPDATE ON AUGUST 16, 2021 Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , Aug. 9, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins PDF Version AUG 2 PROTALIX BIOTHERAPEUTICS ANNOUNCES SUBMISSION OF TYPE A MEETING REQUEST TO THE FDA CARMIEL, Israel , Aug. 2, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based PDF Version JUN 28 PROTALIX BIOTHERAPEUTICS TO PARTICIPATE IN A FIRESIDE CHAT ON JUNE 30, 2021 Zacks Investment Research to host webcast and conference call at 9:00 a.m. EDT CARMIEL, Israel , June 28, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant PDF Version PAGINATION Current page 1 Page 2 Page 3 Next page next › Last page last » 2021 Shareholder Tools Print Page RSS Feeds E-mail Alerts ABOUT About Protalix Management Board of Directors Scientific Advisory Board TECHNOLOGY ProCellEx® Platform From Concept to Market PIPELINE Pipeline Pegunigalsidase alfa (PRX-102) AIR DNase (PRX-110 ) OPRX-106 CONTACT Contact Us Collaborations © 2021 Protalix Ltd. All rights reserved. | Privacy Policy | Terms of use